Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sistemic and Roslin Cells have inked a memorandum of understanding (MoU) to promote the development of new technologies to standardize the manufacturing of stem cells for their use in cell therapy and drug development screening.
Subscribe to our email newsletter
The tie up is expected to advance the use of stem cells for cell therapies and research.
Sistemic CEO Jim Reid said they have been using SistemQC microRNA based service with clients working in these fields to help them gain a greater molecular understanding of their stem cell systems and have built a comprehensive understanding of the issues this sector currently faces.
"We believe that our SistemQC, microRNA approach will play a key part in delivering these enhanced tools and in collaboration with Roslin set the standard for stem cell characterization and quality," Reid said.
Roslin CEO Aidan Courtney said the collaboration with Sistemic will enable them to improve their production processes and deliver more extensive and valuable data to those using their cells.
Scotland-based Sistemic’s suite of tools for the Cell Therapy community includes SistemQC which is used to characterise cells including stem cells (Cell Identity, Purity, Potency, and Safety) as well as monitoring the QC of production.
In addition, the drug development markets are served through a range of products which include SistemTOX, SistemKB and SistemRNA.